The First-90 Diagnostic: a sponsor-side framework for evaluating a new PE-backed CEO
Every PE-backed CEO inherits the same first 90 days. A signed deal. A new sponsor. A team that did not choose them. A value creation plan written by people who do not have to execute it. And a clock that started ticking before they got the keys.
McKinsey calls this the "credibility sprint." Alvarez & Marsal calls it the "first 100 days." Bain has its own version. They are all variants of the same thing. They all have the same problem. The playbooks are written for the CEO. The board wants something different. The board wants a diagnostic.
Here it is. The First-90 Diagnostic. Five questions a sponsor should expect a new PE-backed CEO to answer cleanly by day 90. If the CEO cannot, the board needs to know it then. Not at month 18.
The framework was developed by Lee McCabe at Claymore Partners from observation across multiple PE-backed engagements where the operating foundation drifted before anyone noticed. It is published here so any sponsor, OP, or CEO can use it.
Why a diagnostic, not a playbook
Playbooks tell a new CEO what to do. Diagnostics tell the sponsor what they have actually got.
Most CEO failure modes in PE-backed companies surface at month 18-24, when the value creation plan has fallen behind and the EBITDA bridge stops bridging. By that point, three quarters of the hold period is gone. The cause is almost never the CEO suddenly losing capability. It is that the gaps the CEO inherited were never properly diagnosed in the first 90 days, and the operating cadence drifted from there.
A diagnostic at day 90 forces clarity early enough to act on it.
The five questions
Question 1. Where is the cash, and where will it be 13 weeks from now?
What you should hear: a 13-week rolling cash forecast with confidence intervals, owned by the CFO, refreshed every Friday. The CEO knows the bottom line of week 13 without looking it up.
What you should worry about: vague answers, deferred to "the finance team," or a forecast that bottoms out somewhere uncomfortable in week 7 that the CEO is "monitoring."
Why it matters: cash discipline is the lowest-effort, highest-signal indicator of executive control in the first 90 days. If a CEO does not own the cash question by day 90, they do not own anything else either.
Question 2. What are the six numbers, and who owns each one?
What you should hear: a one-page operating dashboard with six (not sixteen, not three) KPIs, each owned by a single named executive, refreshed weekly, presented at every operating review. The CEO can recite all six and what changed since last week without notes.
What you should worry about: a dashboard with 20+ metrics, no named owners, refreshed monthly. Or the worst sign: a dashboard that has been in place for six months with no metric ever changing.
Why it matters: the six numbers are how the CEO controls the business. If they have not picked six by day 90, they are still navigating by anecdote.
Question 3. What is the one thing that has to change in revenue, and what is the bet?
What you should hear: a clear statement of the single biggest gap in commercial execution. Wrong channel mix, soft conversion, weak retention, mispriced product, wrong segment. Plus a 90-day experiment with a clear hypothesis, owner, timeline, and success metric.
What you should worry about: a list of seven initiatives, all of which "are progressing." Or worse: "we are still diagnosing."
Why it matters: 90 days in, the CEO should have already picked a bet. Not finished the bet. Picked it. A CEO who cannot name the one biggest revenue gap by day 90 does not have a thesis, just a calendar.
Question 4. Which two people on the team would you rebuy at full price today, and which two would you not?
What you should hear: clear names, with reasoning, and an action plan for the "not" answers. Either an upgrade plan, a development plan with a deadline, or an exit plan with a date.
What you should worry about: hedging. "Everyone is doing well." "I am still getting to know the team." At day 90, that is not learning. That is avoiding.
Why it matters: PE-backed companies that exceed plan upgrade 1-2 senior seats in the first six months. PE-backed companies that miss plan rarely change anyone in the first year. The diagnostic at day 90 does not require the CEO to have moved. It requires them to know who they would move if they could.
Question 5. What is the single thing you will know in 90 days that you do not know now, and how will you know it?
What you should hear: a specific, named uncertainty about the market, the team, the product, or the channel. Plus a defined learning experiment designed to resolve it by day 180. With a budget. With a deadline.
What you should worry about: a vague "we will see how the market develops." Or no answer.
Why it matters: the second 90 days has to be built on a hypothesis the first 90 days produced. If the CEO does not have a learning agenda at day 90, the next 90 days will be reactive, not directed.
How to use the diagnostic
For the sponsor: schedule the diagnostic at day 85. Make it formal. Send the questions in advance. This is not a gotcha. Send them to the CEO and the operating partner together. Let the CEO present. Let the OP commentate. Take notes.
For the CEO: do not wait for day 85. Run the diagnostic on yourself at day 60. If you cannot answer cleanly, you have 30 days to fix it. That is better than discovering it in the boardroom.
For the operating partner: the diagnostic gives you a structured way to assess CEO readiness without seeming to grade them. The questions are about the business. The answers tell you about the CEO.
What the diagnostic deliberately leaves out
This framework intentionally does not assess strategic plans, technology roadmaps, marketing strategy, market positioning, capital structure, or board governance. Those matter. Just not in the first 90 days. A CEO who has answers to the five questions above has built the operating foundation that lets the bigger strategic questions be answered well in months 4-12.
A CEO who does not has built nothing yet, no matter how good the strategic plan looks.
How this compares to other frameworks
Other first-100-days frameworks (McKinsey, A&M, SCALE-100, Catalant) focus on what the CEO should do. Listening tours, quick wins, team upgrades, communication plans. They are not wrong. They are CEO-side tools.
The First-90 Diagnostic is a sponsor-side tool. It assumes the CEO has read the playbooks. It asks whether the playbook is working.
Both are needed. Neither replaces the other.
For the firms PE sponsors actually hire when the 90-day diagnostic surfaces gaps too big for internal capacity, see top 10 private equity value creation firms.
FAQ
What is the First-90 Diagnostic?
The First-90 Diagnostic is a five-question framework that PE sponsors and operating partners use at day 90 of a new portfolio company CEO's tenure to assess whether the operating foundation is in place. It covers cash discipline, operating KPIs, the revenue thesis, team upgrade decisions, and the second-90-day learning agenda. It is intentionally a diagnostic tool for the board, not a playbook for the CEO.
Why use a diagnostic at day 90 instead of waiting for the first quarterly board review?
Most PE-backed CEO failure modes do not surface until month 18-24, when three-quarters of the hold period is gone. The root cause is almost always that gaps inherited at close were never diagnosed early enough. A structured diagnostic at day 90 forces clarity at a point where corrective action still has time to compound through the value creation plan.
Who should run the First-90 Diagnostic?
The sponsor partner who owns the deal, supported by the operating partner assigned to the asset. The CEO presents. The OP commentates. The structured questions remove the awkwardness of "grading" the CEO directly. The conversation is about the business, but the answers reveal CEO readiness.
How does the First-90 Diagnostic differ from McKinsey or A&M first-100-days playbooks?
McKinsey, Alvarez & Marsal, Catalant, and others publish CEO-side playbooks for what the CEO should do in their opening quarter. The First-90 Diagnostic is sponsor-side. It assesses whether the CEO has done it. Both are useful.
Can the First-90 Diagnostic be used outside private equity?
Yes. Any board-level governance structure with a new CEO benefits from the same five questions. The framework is most acute in PE-backed contexts because the hold period is compressed and the value creation plan is explicit, but the underlying logic is universal.
